Prescription drug · NDA
Nexletol (Bempedoic acid) NDC 72426-118
Bempedoic acid 180 mg/1 · Tablet, Film coated · Oral · Esperion Therapeutics, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 72426-118-03 | 7242601180372426011803 | 30 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (72426-118-03)Marketed from Mar 6, 2020 | |
| 72426-118-99 | 7242601189972426011899 | 7 TABLET, FILM COATED in 1 BLISTER PACK (72426-118-99)Marketed from Mar 6, 2020 · Sample package |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Nexletol
- Generic name (nonproprietary)
- bempedoic acid
- Active ingredients
- Bempedoic acid — 180 mg/1
- Dosage form
- Tablet, Film coated
- Route
- Oral
- Labeler
- Esperion Therapeutics, Inc.NDC labeler code 72426
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 211616
- Marketing start
- Listing expires
- Other FDA classes
- Adenosine Triphosphate-Citrate Lyase Inhibitors (Mechanism)
- Identifiers
- Product ID 72426-118_e67aa4eb-b86f-4cc0-8a38-e8405de2a113SPL ID e67aa4eb-b86f-4cc0-8a38-e8405de2a113SPL set ID 88d06d89-a3da-40b4-b273-8f4f7d56c4c9RxCUI 2282408, 2282414UNII 1EJ6Z6Q368UPC 0372426118035
- Pharmacologic class
- Adenosine Triphosphate-Citrate Lyase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N472426011803followed by a unit qualifier and the quantityPackage 72426-0118-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
NEXLETOL is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). as an adjunct to diet and exercise, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). NEXLETOL, an adenosine triphosphate-citrate lyase (ACL) inhibitor, is indicated: to reduce the…
Excerpt only. Read the full label for complete information.
About NDC 72426-118
- What is NDC 72426-118?
- 72426-118 is the product NDC for Nexletol (bempedoic acid), Bempedoic acid 180 mg/1 tablet, film coated, listed with the FDA by Esperion Therapeutics, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Nexletol (Bempedoic Acid).
- What is the active ingredient?
- Bempedoic acid.
- Who is the labeler?
- Esperion Therapeutics, Inc., NDC labeler code 72426. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Nexletol?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.